Editorial: The individualization of antiplatelet therapy in coronary artery disease: escalation or de-escalations.
作者信息
Lee Sang Yeub, Geisler Tobias, Motovska Zuzana, Jeong Young-Hoon
机构信息
CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Republic of Korea.
Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
出版信息
Front Cardiovasc Med. 2023 Jun 6;10:1219689. doi: 10.3389/fcvm.2023.1219689. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: The individualization of antiplatelet therapy in coronary artery disease: escalation or de-escalations.社论：冠状动脉疾病抗血小板治疗的个体化：强化还是弱化
Front Cardiovasc Med. 2023 Jun 6;10:1219689. doi: 10.3389/fcvm.2023.1219689. eCollection 2023.
2
Individualized or Uniform De-Escalation Strategies for Antiplatelet Therapy in Acute Coronary Syndrome: A Review of Clinical Trials with Platelet Function Testing and Genetic Testing-Based Protocols.个体化或统一的抗血小板治疗降级策略在急性冠状动脉综合征中的应用：基于血小板功能检测和基因检测方案的临床试验综述。
Int J Mol Sci. 2023 May 22;24(10):9071. doi: 10.3390/ijms24109071.
3
De-escalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy?冠心病患者抗血小板治疗的降阶梯：是时候改变我们的策略了吗？
Eur J Intern Med. 2023 Apr;110:1-9. doi: 10.1016/j.ejim.2022.12.008. Epub 2022 Dec 25.
4
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.经皮冠状动脉介入治疗的急性冠状动脉综合征患者的抗血小板治疗降级指导（TROPICAL-ACS）：一项随机、开放标签、多中心试验。
Lancet. 2017 Oct 14;390(10104):1747-1757. doi: 10.1016/S0140-6736(17)32155-4. Epub 2017 Aug 28.
5
Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis.接受经皮冠状动脉介入治疗的冠心病患者应采用延长、标准或降阶梯抗血小板治疗？一项序贯、双变量、有影响力的网状荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):717-727. doi: 10.1093/ehjcvp/pvac020.
6
Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium.定义冠心病患者抗血小板治疗的调节策略：来自学术研究联盟的共识文件。
Circulation. 2023 Jun 20;147(25):1933-1944. doi: 10.1161/CIRCULATIONAHA.123.064473. Epub 2023 Jun 19.
7
De-escalation versus standard dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.经皮冠状动脉介入治疗患者的降级治疗与标准双联抗血小板治疗的比较：系统评价和荟萃分析。
Platelets. 2020;31(1):15-25. doi: 10.1080/09537104.2019.1574969. Epub 2019 Feb 13.
8
[New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention].抗血小板治疗的新前沿：急性冠状动脉综合征或经皮冠状动脉介入治疗后的指导治疗与降阶梯治疗
G Ital Cardiol (Rome). 2023 Feb;24(2):99-109. doi: 10.1714/3963.39417.
9
Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.基于普拉格雷的急性冠状动脉综合征患者经皮冠状动脉介入治疗后双联抗血小板治疗降级（HOST-REDUCE-POLYTECH-ACS）：一项开放标签、多中心、非劣效性随机试验。
Lancet. 2020 Oct 10;396(10257):1079-1089. doi: 10.1016/S0140-6736(20)31791-8. Epub 2020 Aug 31.
10
Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review.接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者双联抗血小板治疗强度或疗程的降低或降级：一篇综述。
Front Cardiovasc Med. 2022 Oct 20;9:1018649. doi: 10.3389/fcvm.2022.1018649. eCollection 2022.
本文引用的文献
1
Comparison of De-escalation of DAPT Intensity or Duration in East Asian and Western Patients with ACS Undergoing PCI: A Systematic Review and Meta-analysis.东亚和西方经皮冠状动脉介入治疗的急性冠脉综合征患者的 DAPT 强度或持续时间降级比较：系统评价和荟萃分析。
Thromb Haemost. 2023 Aug;123(8):773-792. doi: 10.1055/s-0043-57030. Epub 2023 Apr 18.
2
Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis.急性冠状动脉综合征的双联抗血小板治疗降级：一项个体患者荟萃分析。
Eur Heart J. 2023 Apr 17;44(15):1360-1370. doi: 10.1093/eurheartj/ehac829.
3
Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes.急性冠状动脉综合征经皮冠状动脉介入治疗后短期 DAPT 与降级治疗
JACC Cardiovasc Interv. 2022 Feb 14;15(3):268-277. doi: 10.1016/j.jcin.2021.11.028.
4
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2021 ACC/AHA/SCAI 冠状动脉血运重建指南：执行摘要：美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
Circulation. 2022 Jan 18;145(3):e4-e17. doi: 10.1161/CIR.0000000000001039. Epub 2021 Dec 9.
5
The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease.东亚悖论：心血管疾病患者当前抗栓策略面临挑战的最新立场声明。
Thromb Haemost. 2021 Apr;121(4):422-432. doi: 10.1055/s-0040-1718729. Epub 2020 Nov 10.
6
Colchicine in Patients with Chronic Coronary Disease.秋水仙碱治疗慢性冠心病
N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31.
7
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.2020年欧洲心脏病学会非持续性ST段抬高型急性冠状动脉综合征患者管理指南
Eur Heart J. 2021 Apr 7;42(14):1289-1367. doi: 10.1093/eurheartj/ehaa575.
8
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.心梗后小剂量秋水仙碱的疗效和安全性。
N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16.
9
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.定义经皮冠状动脉介入治疗患者的高出血风险：来自高出血风险学术研究联合会的共识文件。
Eur Heart J. 2019 Aug 14;40(31):2632-2653. doi: 10.1093/eurheartj/ehz372.
10
Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry.阿司匹林治疗与经皮冠状动脉介入治疗后的结局：ISAR-ASPI 注册研究结果。
J Am Coll Cardiol. 2014 Sep 2;64(9):863-71. doi: 10.1016/j.jacc.2014.05.049.
Zotero 插件